Science Explorer Back to mapMap
Institution · Merus (Netherlands)

Most cited papers from Merus (Netherlands)

What are the most cited papers from Merus (Netherlands)?

The most cited paper from Merus (Netherlands) is "A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies" (Chunyan Wang, Rien van Haperen, Francisco J. Gutierrez-Alvarez et al., 2021), with 212 citations. Next come "Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial" (197) and "Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors" (171).

Showing 50 of 72 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies Chunyan Wang, Rien van Haperen, Francisco J. Gutierrez-Alvarez et al. · Nature Communications Open access 17 Mar 2021 212
2 Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial Juliann Chmielecki, Tony S.K. Mok, Yi-Long Lung Cancer Wu et al. · Nature Communications Open access 27 Feb 2023 197
3 Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors Bram Herpers et al. · Nature Cancer Open access 25 Apr 2022 171
4 Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements Alison M. Schram et al. · Cancer Discovery Open access 8 Feb 2022 171
5 A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma Fathima Zumla Cader, Xihao Sherlock Hu, Walter L. Goh et al. · Nature Medicine Open access 10 Aug 2020 142
6 Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer Alison M. Schram et al. · New England Journal of Medicine Open access 5 Feb 2025 134
7 A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade Cecile A. W. Geuijen et al. · Nature Communications Open access 21 Jul 2021 116
8 Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade Cecile A. W. Geuijen, Camilla De Nardis, David Maussang et al. · Cancer Cell Open access May 2018 110
9 Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells Guoying Zhou, Ruby Lieshout, Gilles S. van Tienderen et al. · British Journal of Cancer Open access 21 May 2022 108
10 A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1 Camilla De Nardis, Linda J. A. Hendriks, Emilie Poirier et al. · Journal of Biological Chemistry Open access 27 Jun 2017 104
11 Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2 -Amplified Gastrointestinal Carcinomas Simonetta Maria Leto, Francesco Paolo Sassi, Irene Catalano et al. · Clinical Cancer Research 21 Aug 2015 104
12 The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers Laura C. Zanetti-Domingues et al. · Nature Communications Open access 12 Oct 2018 99
13 Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform Alex Klarenbeek, Khalil El Mazouari, Aline Desmyter et al. · mAbs Open access 27 May 2015 95
14 A Major Histocompatibility Complex·Peptide-restricted Antibody and T Cell Receptor Molecules Recognize Their Target by Distinct Binding Modes Martin Hülsmeyer, Patrick Chames, Roman Christian Hillig et al. · Journal of Biological Chemistry Open access 10 Nov 2004 78
15 Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments Gerhard Held, Mitsutoshi Matsuo, Malka Epel et al. · European Journal of Immunology 5 Aug 2004 71
16 Antibody cocktails: next-generation biopharmaceuticals with improved potency Ton Logtenberg · Trends in biotechnology Review 8 Aug 2007 71
17 MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir et al. · Expert Opinion on Biological Therapy Open access 3 Jul 2019 63
18 Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer Tristan Gallenne, Kenneth N. Ross, Nils L. Visser et al. · Oncotarget Open access 15 Mar 2017 49
19 CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses Tim J A Hutten, Soley Thordardottir, Hanny Fredrix et al. · The Journal of Immunology 27 Aug 2016 46
20 The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque et al. · Future Oncology Open access 13 Feb 2024 43
21 Qualitative and Semiquantitative Analysis of Composite Mixtures of Antibodies by Native Mass Spectrometry Sara Rosati, Natalie Thompson, Arjan Barendregt et al. · Analytical Chemistry 10 Aug 2012 42
22 Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications Renée C.G. de Bruin, Sinéad M. Lougheed, Liza van der Kruk et al. · Clinical Immunology Open access 2 Jul 2016 40
23 Generation of stable cell clones expressing mixtures of human antibodies John de Kruif, Arjen Kramer, Roy Nijhuis et al. · Biotechnology and Bioengineering 16 Apr 2010 38
24 Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry Natalie Thompson, Linda J. A. Hendriks, John de Kruif et al. · mAbs Open access 11 Nov 2013 37
25 Development of Plasmodium falciparum liver-stages in hepatocytes derived from human fetal liver organoid cultures Annie Yang, Devanjali Dutta, Kai Kretzschmar et al. · Nature Communications Open access 2 Aug 2023 36
26 Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker et al. · Investigational New Drugs Open access 5 May 2018 34
27 Systematic study of tissue factor expression in solid tumors Johann Sebastian De Bono, Jeffrey R. Harris, Saskia Maria Burm et al. · Cancer Reports Open access 13 Aug 2022 32
28 Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML Pieter Fokko van Loo, Robert P. Doornbos, Harry Dolstra et al. · Blood 3 Dec 2015 32
29 Estimands for overall survival in clinical trials with treatment switching in oncology Juliane Manitz, Natalia Kan‐Dobrosky, Hannes Buchner et al. · Pharmaceutical Statistics 3 Oct 2021 31
30 Estimand framework: Are we asking the right questions? A case study in the solid tumor setting Michelle Casey, Evgeny Degtyarev, María José Lechuga et al. · Pharmaceutical Statistics 5 Nov 2020 25
31 Human Immunoglobulin Repertoires against Tetanus Toxoid Contain a Large and Diverse Fraction of High-Affinity Promiscuous VH Genes John de Kruif, Arjen Kramer, Therèse Visser et al. · Journal of Molecular Biology 18 Feb 2009 24
32 Heparan sulfate proteoglycan expression in the regenerating zebrafish fin Sebastian Keil, Mansi Gupta, Michael Brand et al. · Developmental Dynamics Open access 26 Feb 2021 22
33 Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects José L. Jiménez, Viktoriya Stalbovskaya, Byron Jones · Pharmaceutical Statistics Open access 27 Dec 2018 22
34 PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation Tiziana Adage, Francesca Del Bene, Francesco Fiorentini et al. · Cytokine 21 Aug 2015 22
35 Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications Ante S. Lundberg, Cecile A. W. Geuijen, Sally A. Hill et al. · Cancers Open access 14 May 2025 21
36 A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage David M. Kallenberg, Vineeta Tripathi, Faiza Javaid et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 25 Jul 2020 21
37 Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos et al. · Clinical Pharmacokinetics Open access 31 Jan 2020 18
38 Selection and characterization of llama single domain antibodies against N-terminal huntingtin Menno H. Schut, Barry A. Pepers, Rinse Klooster et al. · Neurological Sciences Open access 7 Oct 2014 18
39 An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model Viki Bockstal, Machteld M. Tiemessen, Rogier Achterberg et al. · Vaccine Open access 9 Oct 2018 15
40 HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design Amy L. Kessler, Roel F. A. Pieterman, Wouter A. S. Doff et al. · npj Vaccines Open access 18 Jan 2025 14
41 1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC) Alison M. Schram, Teresa Mercade Macarulla, James M. Cleary et al. · Annals of Oncology Open access Oct 2023 14
42 LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC Jean‐Pascal Machiels, Jérôme Fayette, Robert I. Haddad et al. · Future Oncology Open access 13 Jun 2025 12
43 411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial Christophe Le Tourneau, J. Fayette, CHRISTIAN EVEN et al. · Annals of Oncology Open access Dec 2024 12
44 Phage display generation of a novel human anti‐ CD 1 A monoclonal antibody with potent cytolytic activity Gitanjali I. Bechan, David W. Lee, Dirk M. Zajonc et al. · British Journal of Haematology Open access 30 Aug 2012 12
45 Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial Sophia M. van der Hoeven, Jan M. Binnekade, Corianne A.J.M. de Borgie et al. · Trials Open access Sep 2015 12
46 Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial Bart Geboers, Florentine E. F. Timmer, Danielle J. W. Vos et al. · Journal for ImmunoTherapy of Cancer Open access Mar 2025 11
47 1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) Alison M. Schram, Kōichi Goto, Dongwook Kim et al. · Annals of Oncology Open access Oct 2023 11
48 Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts Hendrik J. Kuiken, Sabin Dhakal, Laura M. Selfors et al. · Oncogene Open access 26 Oct 2021 10
49 Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ) María Alsina, Andréa Varga, Alessio Amatu et al. · Annals of Oncology Open access Oct 2018 10
50 Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor Elisa Fontana, Gonzalo Torga, Raluca Maria Fostea et al. · JCO Precision Oncology Open access Aug 2022 9

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.